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Centre Hépato-Biliaire Hôpital Paul Brousse, Villejuif, FranceWilson disease (WD) is a rare autosomal recessive disorder of Cu
metabolism linked to dysfunction of the Cu translocase ATP7B
expressed in hepatocytes [1]. ATP7B is critical in the distribution
and elimination of excess Cu from the organism. Malfunctioning
of the translocase interferes with the distribution of Cu among
organs and tissues and results in the imbalance between Cu
absorption and excretion, thus causing Cu toxicosis.
The levels of Cu regulate the distribution and trafﬁc of ATP7B
in the hepatocyte. While at normal Cu concentrations, ATP7B
remains in the TGN (trans-Golgi network) to supply Cu to the
newly synthesized cuproproteins; at Cu concentrations exceed-
ing the physiological limits it is transferred to the membranes
of the bile canaliculi to dissipate the toxic levels of Cu [2].
Proper cellular distribution and functioning of ATP7B requires
the coordinated interaction between its separate modules.
Whereas the six Cu+-binding domains in its long N-cytoplasmic
domain play a major role in the acceptance of Cu+ and in control-
ling the phosphorylation, trafﬁc, and activity of the translocase,
the clustering of its eight transmembrane helixes forms the Cu+
pore, and the connecting loops in the cytoplasmic side are
involved in the cyclic phosphorylation that controls the activity
of the translocase (Fig. 1A and B) [3]. In addition, there is evi-
dence that the C-cytoplasmic domain may also play an important
role in the trafﬁc and cellular distribution of the translocase [3,4].
Over 300 mutations in the ATP7B gene have been associated
with WD, the majority missense mutations (60%). Mutations
affecting to different extents the binding of Cu, the cyclic phos-
phorylation, trafﬁc, and posttranslational modiﬁcations of ATP7B
as well as its physiological interaction with other proteins, may
potentially interfere with the dual role of ATP7B in excreting
excess Cu into the bile and in the biosynthesis of the ceruloplas-
min essential for proper iron (Fe) metabolism.
The most prevailing mutations in Wilson patients are
H1069Q/G in Europe and North America, and R778L in southeast
Asia [5]. Though H1069 residue plays a critical role in the ATP-
binding to the N-domain of ATP7B, the demonstration that theJournal of Hepatology 20
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Open access under CC BY-NC-ND license.H1069Q mutant is retained and quickly degraded in the ER sug-
gests that this is the primary cause of the WD. The same trafﬁc
defect has been found in studies of the R778L mutant [6]. Besides,
the association of WD with more than 40 different mutations in
the N-site of ATP7B and the fact that only four of these mutations
affect residues implicated in ATP-binding, point to the impor-
tance of cooperation between a large number of residues in the
construction of a functional N-domain. The disruption of
ATP7B-trafﬁcking and the hampering of its phosphorylation pro-
vokes its dysfunction in the hepatocyte and explains the inhibi-
tion of Cu elimination into the bile. Interestingly, the liver from
patients with G943S and M769V mutations, that inhibit the api-
cal trafﬁcking of ATP7B without interfering with its retention in
the TGN, produces normal ceruloplasmin levels and as a result
may not develop severe CNS intoxication.
Clinical symptoms in WD include cirrhosis and chronic hepa-
titis that end in liver failure, neurological defects that course with
parkinsonian symptoms and seizures, and psychiatric features
[7]. The Kayser–Fleischer ring, a deposition of Cu visible as a
golden ring in the periphery of the cornea, low serum levels of
ceruloplasmin, and high levels of Cu in the urine are helpful in
the diagnosis of the disease. The age of presentation of the WD
syndrome, the predominance of hepatic versus neurological
symptoms and their severity are strikingly variable. Excessive
Cu-derived oxidants produced by free Cu2+ - catalyzed Fenton
reactions and reduced superoxide dismutase and glutathione
activities, appear to contribute decisively to the development
and progression of liver abnormalities in WD [8]. Furthermore,
the toxic accumulation of Cu and the development of hepatic
abnormalities without neurological symptoms in a group of WD
patients is mimicked in the Cu toxicosis developed by the Long-
Evans cinnamon rat (50 deletion) and the ‘toxic milk’ mouse.
Genotype variations in the mutations may partly explain the var-
iability behind the clinical symptoms but is also likely that this
also results from the activity of modiﬁer genes and gene-environ-
ment interactions. Moreover, increased binding of Wilson’s dis-
ease ATP7B with COMMD1, a negative regulator of protein
stability involved in the quality control of ATP7B and absent in
Bedlington terriers suffering from copper toxicosis, results in a
decrease of their stability that may result in the ampliﬁcation
of the mutation effects and partially explains the clinical hetero-
geneity observed in WD [9].10 vol. 53 j 1151–1153
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Fig. 1. Cyclic phosphorylation–dephosphorylation of ATP7B and vectorial transport of Cu through the ion channel. Five Cu binding domains (CBD) are aligned along
the N-cytoplasmic end of ATP7B. The chaperone Atox1 transfers Cu+ to the CBD2 [1]. The subsequent ﬁlling of CBDs1–4 with Cu+ provokes structural changes that facilitate
the binding of ATP to the N-site [2], bringing bound ATP in close proximity to the phosphorylation site [3] and facilitating the binding of a Cu+ atom by the two juxtaposed
Cys in the plane of the transmembrane domains TM1 and TM2 [3]. Next, ﬁlling of CBDs5 and 6 with Cu+ favours the transfer of a Cu+ atom to the CPC motif in TM6 [3].
Phosphorylation of the Asp residue in the P-site [4] closes the access to the ion channel from the cytoplasm and facilitates the reception of the translocated Cu+ by the
exofacial vestibule. Cu+ is then released at the opposite side of the membrane and dephosphorylation of Asp-P by the phosphatase in the A-site [5] completes the phospho-
dephosphorylation cycle [6] and resets the channel to basal conditions. (B) Point mutations ( G85V, R778L, H1069Q, C1104F, V1262F, G1341V, S1363F)
changes the levels, cellular distribution, and activity of ATP7B and results in Wilson disease (WD). (C) At physiological concentrations of Cu in the hepatocyte, ATP7B
transfers the Cu+ donated by Atox1 to the newly synthesized cuproproteins (i.e. ceruloplasmin, CP) moving through the trans-Golgi network (TGN). The increase in Cu
concentration beyond physiological levels in the hepatocyte provokes the bulk translocation of ATP7B from the TGN to the membrane of the bile canaliculi where it
mediates the elimination of excess Cu into the bile. Restoration of the physiological levels of Cu results in recycling of ATP7B to the TGN; TJ: Tight junction, SA: serum
albumin. (D) Elimination of Cu by the hepatocyte into the bile is decreased in WD patients as compared to healthy individuals (N), causing Cu toxicosis. The main targets of
toxic Cu are the brain and liver. Low resorption of Cu in the kidney results in high levels of Cu in the urine. The volume of Cu ﬂow into organs and body ﬂuids is indicated by
the arrow size.
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The capacity of Zn to induce metallothionein (MT) and the for-
mation of tight MT–Cu complexes in the intestinal mucosa
explains the effectiveness of the oral administration of Zn acetate
in reducing dietary Cu absorption and the levels of intestinal
haefestin, responses that ameliorate the clinical manifestations
associated with Cu and iron accumulation in WD patients [10].Conﬂict of Interest
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